<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03942094</url>
  </required_header>
  <id_info>
    <org_study_id>Nilotinib20190426</org_study_id>
    <nct_id>NCT03942094</nct_id>
  </id_info>
  <brief_title>Nilotinib for First-line Newly Diagnosed CML-CP Patients</brief_title>
  <official_title>Efficacy and Safety of Nilotinib as the First-line Treatment for Patients With Newly Diagnosed Chronic-phase Chronic Myeloid Leukemia: a Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Second People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhongshan City People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Hospital of Guangdong Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huazhong University of Science and Technology Union Shenzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dongguan People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Longgang District Central Hospital of Shenzhen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shenzhen Second People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase IIIb, multi-centre, single-arm, open-label, prospective study investigating&#xD;
      the efficacy and safety of nilotinib as the first-line treatment for the adult patients with&#xD;
      newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) in China. Nilotinib 300 mg&#xD;
      BID will be provided in this study. The assessment for the primary efficacy endpoint will be&#xD;
      performed at 18 months and the rate of patients obtaining MR4.5 will be measured at this time&#xD;
      point. Secondary endpoints include the complete hematologic response(CHR) and the rates of&#xD;
      major molecular reactions (MMR) by 3, 6, 9,12,18 and 24 months; event free survival (EFS);&#xD;
      overall survival (OS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Molecular response (MR) 4.5 at 18 months of nilotinib 300 mg twice a day</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Molecular Response 4.5 at 3, 6, 9, 12, 24 months of nilotinib</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Molecular Response at 3, 6, 9, 12, 24 months of nilotinib</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of CCyR (complete cytogenetic responses: bone marrow Philadelphie positive at 0 % on at least 20 metaphases) at 3, 6, 9, 12, 24 months of nilotinib.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>24 months</time_frame>
    <description>Survival since randomization without any event defined as loss of CHR, loss of PCyR or CCyR, death from any cause, progression towards accelerated phase or blast crisis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
    <description>Survival without death from any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Myeloid Leukemia, Chronic Phase</condition>
  <condition>Nilotinib</condition>
  <arm_group>
    <arm_group_label>Nilotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib</intervention_name>
    <description>Nilotinib (Tasigna ®), capsules of 150 mg&#xD;
Nilotinib 2 capsules of 150 mg, orally, twice daily</description>
    <arm_group_label>Nilotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients&#xD;
&#xD;
          -  Newly diagnosed CP-CML within 6 months prior to study entry, positive Philadelphia&#xD;
             chromosome or positive BCR-ABL (M-bcr transcript)&#xD;
&#xD;
          -  Age ≥ 18 years old (no upper age limit given)&#xD;
&#xD;
          -  CML-CP defined by primordial cells in peripheral blood or bone marrow &lt;20%, basophils&#xD;
             in peripheral blood &lt;20%, platelets ≥100 x 109/L(≥100,000/mm3), except for&#xD;
             hepatosplenomegaly&#xD;
&#xD;
          -  Patient for whom treatment with Imatinib within 2 weeks is expected No other CML&#xD;
             treatment except for hydroxyurea and/or anagrelide and/or IFN ECOG score 0 to 2&#xD;
&#xD;
          -  Organ function defined by total serum bilirubin levels &lt; 1.5 × the upper limit of the&#xD;
             normal range (ULN), SGOT and SGPT &lt; 2.5 UNL, creatinine &lt; 1.5 × ULN, amylase and&#xD;
             lipase ≤ 1.5 × ULN and alkaline phosphatase ≤ 2.5 × ULN not directly related to the&#xD;
             CML&#xD;
&#xD;
          -  Laboratory values defined by potassium ≥ LLN, magnesium ≥ LLN, phosphate ≥ LLN, total&#xD;
             calcium (correction for serum albumin) ≥ LLN&#xD;
&#xD;
          -  No planned allogeneic stem cell transplantation&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients confirmed to have a T315I mutation&#xD;
&#xD;
          -  TKIs are not allowed to be treated prior to entering the study, unless the patient has&#xD;
             an emergency pending the start of the study, and any dose of commercial imatinib may&#xD;
             be used to the patient, but no more than 2 weeks&#xD;
&#xD;
          -  Treatment with IFN for more than 3 mouths&#xD;
&#xD;
          -  Impaired cardiac function including any of the following:&#xD;
&#xD;
               1. Complete left bundle branch block&#xD;
&#xD;
               2. Right bundle branch block plus left anterior hemiblock,bifascicular block&#xD;
&#xD;
               3. Use of a ventricular-paced pacemaker&#xD;
&#xD;
               4. Congenital long QT syndrome&#xD;
&#xD;
               5. Clinically significant ventricular or atrial tachyarrhythmias&#xD;
&#xD;
               6. Clinically significant resting bradycardia (&lt;50 beats per minute)&#xD;
&#xD;
               7. QTcF &gt;450 msec on screening ECG.If QTcF &gt;450 msec and electrolytes are not within&#xD;
                  normal ranges before nilotinib dosing, electrolytes should be corrected and then&#xD;
                  the patient rescreened for QTcF criterion&#xD;
&#xD;
               8. Myocardial infarction within 12 months prior to starting nilotinib&#xD;
&#xD;
               9. Other clinical significant heart disease (e.g. unstable angina,congestive heart&#xD;
                  failure,uncontrolled hypertension)&#xD;
&#xD;
          -  Patients who are confirmed CNS infiltration by cytopathology&#xD;
&#xD;
          -  Concurrent uncontrolled medical conditions (e.g. uncontrolled diabetes, active or&#xD;
             uncontrolled infections)&#xD;
&#xD;
          -  Congenital or acquired bleeding tendency&#xD;
&#xD;
          -  Patients who have undergone major surgery ≤ 4 weeks prior to starting study drug or&#xD;
             who have not recovered from side effects of such therapy&#xD;
&#xD;
          -  Received other study medications within 30 days (defined as drugs that cannot be used&#xD;
             based on approved indications)&#xD;
&#xD;
          -  Patients unwilling or unable to comply with the protocol&#xD;
&#xD;
          -  Patients with a history of another primary malignancy that is currently clinically&#xD;
             significant or currently requires active intervention&#xD;
&#xD;
          -  Concomitant medications known to be strong inducers or inhibitors of the CYP450&#xD;
             Isoenzyme CYP3A4 (for example, erythromycin, ketoconazole, itraconazole, voriconazole,&#xD;
             clarithromycin, telithromycin, ritonavir, and midazolam)&#xD;
&#xD;
          -  Impaired gastrointestinal function or disease that may alter the absorption of study&#xD;
             drug (e.g.ulcerative disease,uncontrolled nausea,vomiting and diarrhea,malabsorption&#xD;
             syndrome,small bowel resection or gastric by-pass surgery)&#xD;
&#xD;
          -  History of acute pancreatitis within 12 months or chronic pancreatitis&#xD;
&#xD;
          -  History of acute or chronic diseases of Liver, pancreas or kidney&#xD;
&#xD;
          -  Concomitant medications with potential QT prolongation&#xD;
&#xD;
          -  Patients who are pregnant or breast feeding or women of reproductive potential not&#xD;
             employing an effective method of birth control.Women of childbearing potential must&#xD;
             have a negative serum pregnancy test within 14 days prior to administration of&#xD;
             nilotinib.Post menopausal women must be amenorrheic for at least 12 months in order to&#xD;
             be considered of non-childbearing potential.Female patients must agree to employ an&#xD;
             effective barrier method of birth control throughout the study and for up to 3 months&#xD;
             following discontinuation of study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shenzhen Second People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518035</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Du, Phd</last_name>
      <phone>075583366388</phone>
      <phone_ext>8196</phone_ext>
      <email>duxingz@medmail.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 6, 2019</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2019</study_first_posted>
  <last_update_submitted>November 11, 2020</last_update_submitted>
  <last_update_submitted_qc>November 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nilotinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

